.
.
.
Exhibit 99.7
CONTACTS:
LORUS THERAPEUTICS INC. CANADIAN MEDIA CONTACT: US MEDIA CONTACT
Corporate Communications Eliza Walsh Jennifer Taylor
Grace Tse Mansfield Communications Inc. Mansfield Communications Inc.
Tel: (416) 798-1200 ext. 380 Tel: (416) 599-0024 Tel: (212) 370-5045
Email: ir@lorusthera.com Email: eliza@mcipr.com Email: jennifer@mcipr.com
LORUS THERAPEUTICS PARTICIPATES IN 2ND ANNUAL ANTISENSE AND SIRNA
TECHNOLOGIES CONFERENCE IN LONDON, ENGLAND
- CEO Jim Wright invited as a feature presenter on antisense technology -
TSX: LOR
OTC BB: LORFF
TORONTO, CANADA, FEBRUARY 17, 2004 - Lorus Therapeutics Inc. ("Lorus") announced
today that Dr. Jim Wright, chief executive officer of Lorus, will be presenting
a comprehensive review of the development of Lorus' GTI-2040 and GTI-2501
antisense drugs today at the 2nd Annual Antisense and siRNA Technologies
Conference in London, England.
Highlighting Lorus' antisense program, Dr. Wright's presentation will discuss
drug targets and their role in cancer, anti-tumor activity, in vitro and in vivo
evidence of antisense mechanism of action, and review the progress Lorus has
made in advancing GTI-2040 and GTI-2501 in clinical and preclinical programs.
"Lorus is pleased to present its science in a forum that includes peers in the
area of antisense drug development," said Jim Wright, chief executive officer of
Lorus. "The conference is an excellent opportunity for an exchange on the latest
research in antisense technology."
The conference brings together leading industry experts to track the new
developments in antisense and siRNA technologies and examine new clinical trial
results and approaches. The event will also endeavour to discuss the medicinal
chemistry behind effective therapeutic design, drug delivery, manufacture and
purification. As the industry broadens its knowledge of this exciting area, this
conference will discuss the strategies and practices in place and ideas for the
future, as well as analyze the prospects and commercial potentials for antisense
technologies.
About Lorus
Lorus is a biopharmaceutical company focused on the research and development of
cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical,
clinical and regulatory expertise by developing new drug candidates that can be
used, either alone, or
in combination, to successfully manage cancer. Through its own discovery efforts
and an acquisition and in-licensing program, Lorus is building a portfolio of
promising anticancer drugs. Late-stage clinical developments and marketing may
be done in cooperation with strategic pharmaceutical partners. Founded in 1986,
Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange
under the symbol LOR, and on the OTC BB exchange under the symbol LORFF.
Forward Looking Statements
Except for historical information, this press release contains forward-looking
statements, which reflect the Company's current expectation and assumptions, and
are subject to a number of risks and uncertainties that could cause actual
results to differ materially from those anticipated. These forward-looking
statements involve risks and uncertainties, including, but not limited to,
changing market conditions, the Company's ability to obtain patent protection
and protect its intellectual property rights, commercialization limitations
imposed by intellectual property rights owned or controlled by third parties,
intellectual property liability rights and liability claims asserted against the
Company, the successful and timely completion of clinical studies, the
establishment of corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the regulatory
approval process, product development delays, the Company's ability to attract
and retain business partners and key personnel, future levels of government
funding, the Company's ability to obtain the capital required for research,
operations and marketing and other risks detailed from time-to-time in the
Company's ongoing quarterly filings, annual information form, annual reports and
20-F filings. We undertake no obligation to publicly update or revise any
forward looking statements, whether as a result of new information, future
events or otherwise.
Lorus Therapeutics Inc.'s press releases are available through the Company's
Internet site: http://www.lorusthera.com.
-30-